CU23404A1 - Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes - Google Patents

Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes

Info

Publication number
CU23404A1
CU23404A1 CU20030270A CU20030270A CU23404A1 CU 23404 A1 CU23404 A1 CU 23404A1 CU 20030270 A CU20030270 A CU 20030270A CU 20030270 A CU20030270 A CU 20030270A CU 23404 A1 CU23404 A1 CU 23404A1
Authority
CU
Cuba
Prior art keywords
polysaccharides
formulations
neisseria meningitidis
meningitidis
similar
Prior art date
Application number
CU20030270A
Other languages
English (en)
Spanish (es)
Inventor
Blanco Sonia Gonzalez
Portilla Tania Carmenate
Espina Maite Delgado
Perez Olivia Niebla
Garcia Gretel Sardinas
Feyt Rolando Pajon
Rubido Julio Cesar Aguilar
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20030270A priority Critical patent/CU23404A1/es
Priority to ARP040104182A priority patent/AR046840A1/es
Priority to PCT/CU2004/000014 priority patent/WO2005049076A1/fr
Publication of CU23404A1 publication Critical patent/CU23404A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CU20030270A 2003-11-19 2003-11-19 Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes CU23404A1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CU20030270A CU23404A1 (es) 2003-11-19 2003-11-19 Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
ARP040104182A AR046840A1 (es) 2003-11-19 2004-11-12 Polisacaridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
PCT/CU2004/000014 WO2005049076A1 (fr) 2003-11-19 2004-11-18 Utilisation de polysaccharides capsulaires de neisseria meningitidis en tant que immunopotentialisateurs administres par voie muqueuse et formulations obtenues

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20030270A CU23404A1 (es) 2003-11-19 2003-11-19 Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes

Publications (1)

Publication Number Publication Date
CU23404A1 true CU23404A1 (es) 2009-08-04

Family

ID=34777988

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20030270A CU23404A1 (es) 2003-11-19 2003-11-19 Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes

Country Status (3)

Country Link
AR (1) AR046840A1 (fr)
CU (1) CU23404A1 (fr)
WO (1) WO2005049076A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001669A (es) 2003-08-12 2006-04-28 3M Innovative Properties Co Compuestos que contienen imidazo-oxima sustituidos.
US7897597B2 (en) 2003-08-27 2011-03-01 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
WO2005023190A2 (fr) 2003-09-05 2005-03-17 3M Innovative Properties Company Traitement pour le lymphome a cellules b cd5+
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2545774A1 (fr) 2003-11-14 2005-06-02 3M Innovative Properties Company Composes d'un anneau d'imidazo substitues par oxime
CA2545825A1 (fr) 2003-11-14 2005-06-02 3M Innovative Properties Company Composes d'un anneau d'imidazo substitue par hydroxylamine
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
EP1701955A1 (fr) 2003-12-29 2006-09-20 3M Innovative Properties Company Imidazoquinolines a substitution arylalcenyle et arylalkynyle
CA2551399A1 (fr) 2003-12-30 2005-07-21 3M Innovative Properties Company Sulfonamides d'imidazoquinolinyle, d'imidazopyridinyle et d'imidazonaphtyridinyle
EP1730143A2 (fr) 2004-03-24 2006-12-13 3M Innovative Properties Company Imidazopyridines, imidazoquinolines, et imidazonaphthyridines a substitution amide
WO2005123080A2 (fr) 2004-06-15 2005-12-29 3M Innovative Properties Company Imidazoquinolines et imidazonaphthyridines substituees par un heterocyclyle contenant un azote
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006009826A1 (fr) 2004-06-18 2006-01-26 3M Innovative Properties Company Thiazoloquinolines et thiazolonaphtyridines substitues par aryloxy et arylalkyleneoxy
WO2006038923A2 (fr) 2004-06-18 2006-04-13 3M Innovative Properties Company Imidazonaphthyridines substituees par aryle
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
US20080119508A1 (en) * 2004-12-30 2008-05-22 3M Innovative Properties Company Multi-Route Administration Of Immune Response Modifier Compounds
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
JP2008530113A (ja) 2005-02-11 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシラミン置換イミダゾ［４，５−ｃ］環化合物および方法
AU2006232377A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
WO2006107851A1 (fr) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Composes cycliques 1-pyrazolo[3,4-c] substitues comme modulateurs de la biosynthese de cytokine destines au traitement d'infections virales et de maladies neoplastiques
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
CN101785857B (zh) * 2010-03-05 2012-09-26 成都安特金生物技术有限公司 一种新的肺炎球菌结合疫苗及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20024224A3 (cs) * 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek

Also Published As

Publication number Publication date
AR046840A1 (es) 2005-12-28
WO2005049076A1 (fr) 2005-06-02

Similar Documents

Publication Publication Date Title
CU23404A1 (es) Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
CY1115308T1 (el) Συνθεσεις εμβολιου οι οποιες περιεχουν ανοσοενισχυτικο εκδοχο σαπωνινης
TW200722101A (en) Novel composition
EP3058954A3 (fr) Compositions immunogènes et procédés
DE122011100054I1 (de) Influenza vakzinzusammensetzungen zur intradermaler verabreichung.
CY1118732T1 (el) Εμβολια κυστιδιων βασει gna1870 για προστασια ευρεως φασματος εναντι νοσων προκαλουμενων απο neisseria meningitidis
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
MX340096B (es) Formulaciones de vacuna meningococica.
NO20064781L (no) Fremgangsmater og adjuvanser for a forbedre immunresponser mot vaksiner og fremgangsmater for anvendelse
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
Riedl et al. The novel adjuvant IC31® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice
WO2006060710A3 (fr) Preparations de vaccins destinees a une administration intradermique, contenant des adjuvants et des agents antigeniques
MX2009000660A (es) Vacuna de influenza.
CY1111916T1 (el) Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος
BRPI0510430A (pt) composições e métodos para vacinação mucosal
DOP2009000239A (es) Vacuna de influenza de emulsion de aceite en agua
PE20190458A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
AR082952A1 (es) Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
AR053661A1 (es) Peptido para entregar vacunas via mucosas
RU2008144180A (ru) Вакцина против микоплазмы и prrsv
AR038311A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
EA200870361A1 (ru) Интраназальное или ингаляционное введение виросом
UY28706A1 (es) Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes
SG160386A1 (en) Novel composition
CY1115921T1 (el) Εμβολιο γριπης